Paper29720221
Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
Chen YL and 9 others. Arthritis Res Ther, 2018. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. Papers, record 29720221. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29720221
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antirheumatic Agents | Major topic |
| Arthritis, Rheumatoid | Major topic |
| Hepatitis B, Chronic | Major topic |
| Adult | |
| Antiviral Agents | |
| Case-Control Studies | |
| Female | |
| Guanine | |
| Hepatitis B virus | |
| Humans | |
| Logistic Models | |
| Male | |
| Middle Aged | |
| Outcome Assessment, Health Care | |
| Remission Induction | |
| Retrospective Studies | |
| Severity of Illness Index | |
| Tenofovir |
Source PubMed
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20699241 | 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. | Ann Rheum Dis | 2010 | https://conductscience.org/library/papers/20699241 | PubMed |
| 2 | 11296944 | Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link. | J Rheumatol | 2001 | https://conductscience.org/library/papers/11296944 | PubMed |
| 3 | 20870315 | [Hepatitis B virus, extrahepatic immunologic manifestations and risk of viral reactivation]. | Rev Med Interne | 2011 | https://conductscience.org/library/papers/20870315 | PubMed |
| 4 | 25447852 | American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. | Gastroenterology | 2015 | https://conductscience.org/library/papers/25447852 | PubMed |
| 5 | 22565315 | Management of rheumatic disease with comorbid HBV or HCV infection. | Nat Rev Rheumatol | 2012 | https://conductscience.org/library/papers/22565315 | PubMed |
| 6 | 22473918 | Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. | Arthritis Care Res (Hoboken) | 2012 | https://conductscience.org/library/papers/22473918 | PubMed |
| 7 | 7921766 | Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination. | Br J Rheumatol | 1994 | https://conductscience.org/library/papers/7921766 | PubMed |
| 8 | 15189743 | Leflunomide in the treatment of rheumatoid arthritis. | Clin Ther | 2004 | https://conductscience.org/library/papers/15189743 | PubMed |
| 9 | 25147433 | Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. | Mediators Inflamm | 2014 | https://conductscience.org/library/papers/25147433 | PubMed |
| 10 | 18512708 | American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. | Arthritis Rheum | 2008 | https://conductscience.org/library/papers/18512708 | PubMed |
| 11 | 20444750 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. | Ann Rheum Dis | 2010 | https://conductscience.org/library/papers/20444750 | PubMed |
| 12 | 15784044 | Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease. | Am J Gastroenterol | 2005 | https://conductscience.org/library/papers/15784044 | PubMed |
| 13 | 16539831 | Rapidly destructive knee arthropathy associated with hepatitis B. | Clin Exp Rheumatol | 2006 | https://conductscience.org/library/papers/16539831 | PubMed |
| 14 | 2290175 | Reactive arthritis after hepatitis B vaccination. | J Rheumatol | 1990 | https://conductscience.org/library/papers/2290175 | PubMed |
| 15 | 9733447 | The development of rheumatoid arthritis after recombinant hepatitis B vaccination. | J Rheumatol | 1998 | https://conductscience.org/library/papers/9733447 | PubMed |
| 16 | 25532827 | Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. | BMC Musculoskelet Disord | 2014 | https://conductscience.org/library/papers/25532827 | PubMed |
| 17 | 15763339 | Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. | J Hepatol | 2005 | https://conductscience.org/library/papers/15763339 | PubMed |
| 18 | 24161836 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. | Ann Rheum Dis | 2014 | https://conductscience.org/library/papers/24161836 | PubMed |
| 19 | 22473917 | 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. | Arthritis Care Res (Hoboken) | 2012 | https://conductscience.org/library/papers/22473917 | PubMed |
| 20 | 22021897 | Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. | Ann Rheum Dis | 2012 | https://conductscience.org/library/papers/22021897 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42027193 | Serological evidence linking viral infections to incident risk of hip and knee osteoarthritis. | Bone Joint Res | 2026 | https://conductscience.org/library/papers/42027193 | PubMed |
| 41782135 | Association between periodontitis and hepatocellular carcinoma across different tumor stages. | BMC Oral Health | 2026 | https://conductscience.org/library/papers/41782135 | PubMed |
| 40260684 | Indications and contraindications to platelet-rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injections). | Knee Surg Sports Traumatol Arthrosc | 2025 | https://conductscience.org/library/papers/40260684 | PubMed |
| 39682184 | Hepatitis and Hepatitis B Virus Reactivation in Everolimus-Treated Solid Tumor Patients: A Focus on HBV-Endemic Areas. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39682184 | PubMed |
| 36188738 | Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. | World J Virol | 2022 | https://conductscience.org/library/papers/36188738 | PubMed |
| 35244954 | Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. | Periodontol 2000 | 2022 | https://conductscience.org/library/papers/35244954 | PubMed |
| 34200522 | Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. | J Clin Med | 2021 | https://conductscience.org/library/papers/34200522 | PubMed |
| 33294150 | Neglected extra-articular manifestations in rheumatoid arthritis patients with normal body mass index: reduced skeletal muscle overlapping overfat. | Ther Adv Chronic Dis | 2020 | https://conductscience.org/library/papers/33294150 | PubMed |
| 32922525 | Reduced skeletal muscle independently predicts 1-year aggravated joint destruction in patients with rheumatoid arthritis. | Ther Adv Musculoskelet Dis | 2020 | https://conductscience.org/library/papers/32922525 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| MMP3 | 4314 | PubTator's text mining | https://conductscience.org/library/genes/4314 | NCBI Gene |
| PLGLA | 285189 | PubTator's text mining | https://conductscience.org/library/genes/285189 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29720221
GET https://conductscience.org/api/papers/v1/29720221/references?page=2